Overview

Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

Status:
Active, not recruiting

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.

Phase:

Phase 1

Details

Lead Sponsor:

The Netherlands Cancer Institute

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab